Keyphrases
Preclinical Testing
75%
Osteosarcoma
75%
Patient-derived Xenograft
75%
Agent-based Testing
25%
Informed Agents
25%
Agent Selection
25%
Clinical Trials
15%
Eribulin
15%
Drug Action
7%
Brentuximab Vedotin
7%
Cyclophosphamide
7%
ALK Inhibitor
7%
Patient Survival
7%
Rapamycin
7%
Etoposide
7%
Cisplatin
7%
Insulin-like Growth Factor 1 Receptor (IGF1R)
7%
Novel Treatments
7%
Eltrombopag
7%
Genetic Changes
7%
Novel Agents
7%
Tumor
7%
Testing Program
7%
Pediatric
7%
In Vitro Data
7%
Children's Oncology Group
7%
Inhibitory Activity
7%
Clinical Trial Development
7%
Medicine and Dentistry
Xenograft
100%
Osteosarcoma
100%
Clinical Trial
28%
Disease
24%
Neoplasm
20%
Pediatrics
20%
Eribulin
15%
Proteomics
9%
Cisplatin
7%
Oncology
7%
In Vitro
7%
Glembatumumab Vedotin
7%
Rapamycin
7%
Gene Mutation
7%
Cyclophosphamide
7%
Etoposide
7%
Drug Activity
7%
ALK Inhibitor
7%
Eltrombopag
7%
Pharmacology, Toxicology and Pharmaceutical Science
Osteosarcoma
75%
Clinical Trial
22%
Disease
15%
Eribulin
15%
Neoplasm
7%
Eltrombopag
7%
Rapamycin
7%
Cyclophosphamide
7%
Etoposide
7%
Cisplatin
7%
Anaplastic Lymphoma Kinase Inhibitor
7%
Glembatumumab Vedotin
7%